News Posts List
Eisai Oncology to Present New Research
05/18/2012
Treatment of Refractory Metastatic Renal Cell Carcinoma (RCC) with Lenvatinib (E7080) and Everolimus
Safer kidney cancer surgery under-used
05/16/2012
An increasingly common and safer type of surgery for kidney cancer is not as likely to be used for older, sicker and poorer patients who are uninsured or rely on Medicare or Medicaid for their health care, according to a new study by researchers at Henry Ford Hospital.
Rosetta Genomics Launches miRview Kidney
05/16/2012
Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the commercial launch of miRview® kidney, the Company's advanced microRNA assay that uses microRNA expression to classify the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview® kidney will be marketed in the U.S. by Rosetta Genomics' oncology sales team beginning this month.
Kidney Cancer Linked to Gum Disease
05/16/2012
There is a strong link between periodontal disease and kidney cancer, a recent research report in the prestigious journal, Lancet Oncology, confirmed that gum disease increases the risk of kidney cancer by around 50%.
Women Cope Better Than Men After Kidney Surgery
05/16/2012
The results of the new study, based on population samples from throughout the U.S., will be presented this week at the American Urological Associations Annual Meeting in Atlanta.
Cancer survival 'still varies greatly'
05/15/2012
Survival rates have risen dramatically for many types of cancer but have hardly improved for others, BBC News reported.
Thyroid abnormalities induced by sunitinib treatment in Japanese
05/15/2012
Sunitinib is a multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma. However, sunitinib often causes hypothyroidism. In this study, we report eight cases with thyroid dysfunction that occurred during sunitinib treatment for advanced renal cell carcinoma.
Pfizer To Present New Data In Advanced Kidney Cancer
05/15/2012
Data from Kidney Cancer Portfolio Further Demonstrate Efficacy and Safety Across Multiple Lines of Therapy.
Pharmaceutical Patient Support Program
05/12/2012
Speak to one of the Oncology Certified Nurses available through SUTENT In Touch. Call 1-877-5-SUTENT (1-877-578-8368). Nurses are available to talk from 9:30 am to 7 pm ET, Monday through Friday.
Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
05/12/2012
Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
News Feed